OBJECTIVES: Helium produces preconditioning by activating prosurvival kinases, but the roles of reactive oxygen species (ROS) or mitochondrial adenosine triphosphate-regulated potassium (K(ATP)) channels in this process are unknown. The authors tested the hypothesis that ROS and mitochondrial K(ATP) channels mediate helium-induced preconditioning in vivo. DESIGN: A randomized, prospective study. SETTING: A university research laboratory. PARTICIPANTS: Male New Zealand white rabbits. INTERVENTIONS: Rabbits (n = 64) were instrumented for the measurement of systemic hemodynamics and subjected to a 30-minute left anterior descending coronary artery (LAD) occlusion and 3 hours of reperfusion. In separate experimental groups, rabbits (n = 7 or 8 per group) were randomly assigned to receive 0.9% saline (control) or 3 cycles of 70% helium-30% oxygen administered for 5 minutes interspersed with 5 minutes of an air-oxygen mixture before LAD occlusion with or without the ROS scavengers N-acetylcysteine (NAC; 150 mg/kg) or N-2 mercaptoproprionyl glycine (2-MPG; 75 mg/kg), or the mitochondrial K(ATP) antagonist 5-hydroxydecanoate (5-HD; 5 mg/kg). Statistical analysis of data was performed with analysis of variance for repeated measures followed by Bonferroni's modification of a Student t test. MEASUREMENTS AND MAIN RESULTS: The myocardial infarct size was determined by using triphenyltetrazolium chloride staining and presented as a percentage of the left ventricular area at risk. Helium significantly (p < 0.05) reduced infarct size (23 +/- 4% of the area at risk; mean +/- standard deviation) compared with control (46 +/- 3%). NAC, 2-MPG, and 5-HD did not affect irreversible ischemic injury when administered alone (49 +/- 5%, 45 +/- 6%, and 45 +/- 3%), but these drugs blocked reductions in infarct size produced by helium (45 +/- 4%, 45 +/- 2%, and 44 +/- 3%). CONCLUSIONS: The results suggest that ROS and mitochondrial K(ATP) channels mediate helium-induced preconditioning in vivo.
OBJECTIVES:Helium produces preconditioning by activating prosurvival kinases, but the roles of reactive oxygen species (ROS) or mitochondrial adenosine triphosphate-regulated potassium (K(ATP)) channels in this process are unknown. The authors tested the hypothesis that ROS and mitochondrial K(ATP) channels mediate helium-induced preconditioning in vivo. DESIGN: A randomized, prospective study. SETTING: A university research laboratory. PARTICIPANTS: Male New Zealand white rabbits. INTERVENTIONS:Rabbits (n = 64) were instrumented for the measurement of systemic hemodynamics and subjected to a 30-minute left anterior descending coronary artery (LAD) occlusion and 3 hours of reperfusion. In separate experimental groups, rabbits (n = 7 or 8 per group) were randomly assigned to receive 0.9% saline (control) or 3 cycles of 70% helium-30% oxygen administered for 5 minutes interspersed with 5 minutes of an air-oxygen mixture before LAD occlusion with or without the ROS scavengers N-acetylcysteine (NAC; 150 mg/kg) or N-2 mercaptoproprionyl glycine (2-MPG; 75 mg/kg), or the mitochondrial K(ATP) antagonist 5-hydroxydecanoate (5-HD; 5 mg/kg). Statistical analysis of data was performed with analysis of variance for repeated measures followed by Bonferroni's modification of a Student t test. MEASUREMENTS AND MAIN RESULTS: The myocardial infarct size was determined by using triphenyltetrazolium chloride staining and presented as a percentage of the left ventricular area at risk. Helium significantly (p < 0.05) reduced infarct size (23 +/- 4% of the area at risk; mean +/- standard deviation) compared with control (46 +/- 3%). NAC, 2-MPG, and 5-HD did not affect irreversible ischemic injury when administered alone (49 +/- 5%, 45 +/- 6%, and 45 +/- 3%), but these drugs blocked reductions in infarct size produced by helium (45 +/- 4%, 45 +/- 2%, and 44 +/- 3%). CONCLUSIONS: The results suggest that ROS and mitochondrial K(ATP) channels mediate helium-induced preconditioning in vivo.
Authors: T Pain; X M Yang; S D Critz; Y Yue; A Nakano; G S Liu; G Heusch; M V Cohen; J M Downey Journal: Circ Res Date: 2000-09-15 Impact factor: 17.367
Authors: Katsuya Tanaka; Dorothee Weihrauch; Franz Kehl; Lynda M Ludwig; John F LaDisa; Judy R Kersten; Paul S Pagel; David C Warltier Journal: Anesthesiology Date: 2002-12 Impact factor: 7.892
Authors: Paul S Pagel; John G Krolikowski; Phillip F Pratt; Yon Hee Shim; Julien Amour; David C Warltier; Dorothee Weihrauch Journal: Anesth Analg Date: 2008-09 Impact factor: 5.108
Authors: Paul S Pagel; John G Krolikowski; Phillip F Pratt; Yon Hee Shim; Julien Amour; David C Warltier; Dorothee Weihrauch Journal: Anesth Analg Date: 2008-09 Impact factor: 5.108
Authors: Leo G Kevin; Enis Novalija; Matthias L Riess; Amadou K S Camara; Samhita S Rhodes; David F Stowe Journal: Anesth Analg Date: 2003-04 Impact factor: 5.108
Authors: Enis Novalija; Srinivasan G Varadarajan; Amadou K S Camara; Jianzhong An; Qun Chen; Matthias L Riess; Neil Hogg; David F Stowe Journal: Am J Physiol Heart Circ Physiol Date: 2002-07 Impact factor: 4.733
Authors: Paul S Pagel; John G Krolikowski; Julien Amour; David C Warltier; Dorothee Weihrauch Journal: J Cardiothorac Vasc Anesth Date: 2009-02-23 Impact factor: 2.628
Authors: Gezina T M L Oei; Michal Heger; Rowan F van Golen; Lindy K Alles; Moritz Flick; Allard C van der Wal; Thomas M van Gulik; Markus W Hollmann; Benedikt Preckel; Nina C Weber Journal: Mol Med Date: 2015-01-20 Impact factor: 6.354
Authors: Kirsten F Smit; Moritz Konkel; Raphaela Kerindongo; Maximilian A Landau; Coert J Zuurbier; Markus W Hollmann; Benedikt Preckel; Rienk Nieuwland; Martin Albrecht; Nina C Weber Journal: Sci Rep Date: 2018-03-19 Impact factor: 4.379